Estonia - Kiestonia - Ravimiamet

actavis group ptc ehf. - imatiniib - õhukese polümeerikattega tablett - 100mg 120tk; 100mg 90tk

Estonia - Kiestonia - Ravimiamet

fresenius kabi deutschland gmbh - imatiniib - õhukese polümeerikattega tablett - 400mg 120tk; 400mg 90tk; 400mg 180tk; 400mg 20tk; 400mg 10tk; 400mg 60tk

Estonia - Kiestonia - Ravimiamet

laboratorios liconsa s.a. - imatiniib - õhukese polümeerikattega tablett - 300mg 4tk; 300mg 24tk; 300mg 28tk; 300mg 60tk; 300mg 120tk; 300mg 90tk; 300mg 20tk; 300mg 1tk

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

novartis europharm limited - imatiniib - precursor cell lymphoblastic leukemia-lymphoma; gastrointestinal stromal tumors; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - antineoplastilised ained - glivec is indicated for the treatment of , adult and paediatric patients with newly diagnosed philadelphia-chromosome (bcr-abl)-positive (ph+) chronic myeloid leukaemia (cml) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed philadelphia-chromosome-positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (mds / mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and / or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfra rearrangement. mõju glivec tulemuste kohta luu-üdi siirdamine ei ole kindlaks. glivec is indicated for: , the treatment of adult patients with kit (cd 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (gist);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patsientidel, kellel on madal või väga madal risk kordumise ei tohiks saada abiaine ravi; ravi täiskasvanud patsientidel, kellel unresectable dermatofibrosarcoma protuberans (dfsp) ja täiskasvanud patsientidel korduva ja / või metastaatilise dfsp, kes ei ole abikõlblikud operatsioon. , täiskasvanud ja pediaatriliste patsientide, tõhususe glivec põhineb üldine hematoloogiline ja tsütogeneetiline ravivastus, ja progression-free survival in cml, hematoloogiline ja tsütogeneetiline ravivastus, ph+ all, mds / mpd, hematoloogiline ravivastus, in hes / cel ja objektiivne ravivastus, täiskasvanud patsientidel unresectable ja / või metastaatilise pÕhisisu ja dfsp ja kordumise-free survival in abiaine pÕhilised. kogemus glivec patsientidel mds / mpd seotud pdgfr geeni taas-kord on väga piiratud (vt lõik 5. välja arvatud äsja diagnoositud kroonilise faasi cml, ei ole kontrollitud uuringud, mis näitab kliiniline kasu või suurenenud ellujäämise eest need haigused.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

accord healthcare s.l.u. - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

pfizer limited - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - sprycel on näidustatud ravi pediaatrilised patsiendid:äsja diagnoositud philadelphia-kromosoom-positiivse kroonilise müeloidse leukeemia kroonilise faasi (ph+ cml cp) või ph+ cml cp resistentsed või talumatus eelneva ravi (sh imatinib. äsja diagnoositud ph+ ägeda lümfoblastilise leukeemia (all) kombinatsioonis keemiaraviga. sprycel on näidustatud ravi täiskasvanud patsientidel, kellel on:äsja diagnoositud philadelphia-kromosoom-positiivse (ph+) kroonilise müeloidse leukeemia (cml) kroonilise faasi;krooniline, kiirendatud või lööklaine faasis cml, mille resistentsus või talumatus eelneva ravi (sh imatinib mesilate;ph+ ägeda lümfoblastilise leukeemia (all) ja lümfisüsteemi lööklaine cml, mille resistentsus või talumatus eelneva ravi. sprycel on näidustatud ravi pediaatrilised patsiendid:äsja diagnoositud ph+ cml krooniline faas (ph+ cml-cp) või ph+ cml-cp resistentsed või talumatus eelneva ravi (sh imatinib.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

pfizer europe ma eeig - bosutiniib (monohüdraadina) - leukeemia, müeloid - antineoplastic agents, protein kinase inhibitors - bosulif on näidustatud ravi täiskasvanud patsientidel, kellel on:äsja diagnoositud krooniline faas (lp) philadelphia kromosoom-positiivse kroonilise müeloidse leukeemia (ph+ cml). cp, kiirendatud etapp (ap), ja plahvatuse etapp (bp) ph+ cml eelnevalt ravitud ühe või mitme türosiinkinaasi inhibiitor(s) [tki(s)] ja kellele imatinib, nilotinib ja dasatinib ei ole asjakohane ravi valikud.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - seedetraktist esinevad stromaal-kasvajad - antineoplastilised ained - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Umoja wa Ulaya - Kiestonia - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.